Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Clinical evidence of the effectiveness of remdesivir in COVID-19 during periods dominated by Delta and Omicron SARS-CoV-2 variants.
  • +10
  • Krystyna Dobrowolska,
  • MichaÅ‚ BrzdÄ™k,
  • Dorota ZarÄ™bska-Michaluk,
  • Piotr Rzymski,
  • Magdalena Rogalska,
  • Anna Moniuszko-Malinowska,
  • Dorota Kozielewicz,
  • Marcin Hawro,
  • Marta Rorat,
  • Katarzyna Sikorska,
  • Jerzy Jaroszewicz,
  • Justyna Kowalska,
  • Robert Flisiak
Krystyna Dobrowolska
Uniwersytet Jana Kochanowskiego w Kielcach Collegium Medicum
Author Profile
Michał Brzdęk
Uniwersytet Jana Kochanowskiego w Kielcach Collegium Medicum
Author Profile
Dorota Zarębska-Michaluk
Uniwersytet Jana Kochanowskiego w Kielcach Collegium Medicum

Corresponding Author:[email protected]

Author Profile
Piotr Rzymski
Uniwersytet Medyczny im Karola Marcinkowskiego w Poznaniu
Author Profile
Magdalena Rogalska
Uniwersytet Medyczny w Bialymstoku
Author Profile
Anna Moniuszko-Malinowska
Uniwersytet Medyczny w Bialymstoku
Author Profile
Dorota Kozielewicz
Uniwersytet Mikolaja Kopernika w Toruniu
Author Profile
Marcin Hawro
Department of Infectious Diseases and Hepatology
Author Profile
Marta Rorat
Uniwersytet Medyczny im Piastow Slaskich we Wroclawiu
Author Profile
Katarzyna Sikorska
Gdanski Uniwersytet Medyczny
Author Profile
Jerzy Jaroszewicz
Slaski Uniwersytet Medyczny w Katowicach
Author Profile
Justyna Kowalska
Warszawski Uniwersytet Medyczny
Author Profile
Robert Flisiak
Uniwersytet Medyczny w Bialymstoku
Author Profile

Abstract

Continuous evaluation of real-world treatment effectiveness of COVID-19 medicines is required due to the ongoing evolution of SARS-CoV-2 and the possible emergence of resistance. Therefore, this study aimed to analyze the outcomes in patients hospitalized with COVID-19 during the pandemic waves dominated by Delta and Omicron variants and treated with remdesivir (RDV) (n=762) in comparison to the demographically and clinically matched group not treated with any antivirals (n=1060). During the Delta wave, the RDV-treated group revealed 2-fold lower mortality (10.8 vs. 23.2%, p<0.001) and 1.5-fold lower during the Omicron-dominated period (11.4 vs. 16.8%, p=0.05). RDV-treated groups were characterized by a lower percentage of patients requiring mechanical ventilation, but the difference was not statistically significant. This study is the first real-world evidence that RDV remains effective during the dominance of more pathogenic SARS-CoV-2 variants and those that cause a milder course of the disease and continues to be an essential element of COVID-19 therapy.
19 Mar 2023Published in Journal of Clinical Medicine volume 12 issue 6 on pages 2371. 10.3390/jcm12062371